CClinicalTrials.gg
Not yet recruitingNCT07637019SHJG-PPUpdated Jun 9, 2026

Clinical Study of Traditional Chinese Medicine in the Treatment of Phlegm-dampness Intrinsic Precocious Puberty

An interventional study of Sanghe Jianghuo Granules and Placebo in Precocious Puberty, sponsored by Children's Hospital of Fudan University. Not yet recruiting at 5 sites in China. Open to female participants aged 5 Years to 9 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Children's Hospital of Fudan University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
5 Years to 9 Years
Sex
Female
01

Study summary

Precocious puberty is characterized by the premature appearance of secondary sexual characteristics. Globally, the timing of puberty onset in children has shown a certain tendency to advance. In China, the incidence of precocious puberty has been increasing year by year. Precocious puberty exerts long-term and systemic impacts on children's health: advanced bone age leads to short stature; earlier sexual development than peers may induce emotional problems such as anxiety and inferiority; it may increase the risk of obesity and type 2 diabetes, posing long-term hazards to cardiovascular health; it may also result in irregular menstruation or dysmenorrhea, exerting indirect effects on reproductive health.

Modern traditional Chinese medicine (TCM) holds that: various factors lead to liver-kidney yin deficiency, hyperactivity of ministerial fire, and early arrival of tian gui (the substance responsible for promoting growth, development and reproduction), thereby triggering premature sexual development. The main syndrome types identified in clinical practice include yin deficiency with fire hyperactivity syndrome, liver stagnation transforming into fire syndrome, and phlegm-dampness internal accumulation syndrome.

Since the late 1970s, the investigators' department has taken the lead in treating precocious puberty with TCM diagnostic methods, proposing that the pathogenesis of precocious puberty lies in "kidney yin deficiency and hyperactivity of ministerial fire", and adopting the therapy of nourishing yin and purging fire for its treatment. A number of studies have confirmed that TCM medicines with the effects of nourishing yin and purging fire can effectively alleviate the yin deficiency with fire hyperactivity syndrome in children, delay the development of secondary sexual characteristics and bone age.

At present, central precocious puberty is mostly treated with gonadotropin-releasing hormone analogs (GnRHa). However, this treatment has the drawback of inhibiting the growth axis, yielding limited benefits for children with advanced bone age, overweight or obesity, and may even affect glucose and lipid metabolism. Moreover, some children with precocious puberty complicated with obesity may be intolerant to this therapy. In contrast, TCM therapy and integrated TCM-Western medicine therapy can effectively delay the development of secondary sexual characteristics and advanced bone age, and improve final adult height, thus being widely applied in China.

Although a large number of relevant studies have been reported in recent years and TCM diagnosis and treatment guidelines for precocious puberty have been formulated, there is still a lack of high-quality evidence-based medical research to support the advantageous aspects of integrated TCM-Western medicine diagnosis and treatment. Additionally, the underlying mechanisms of diagnosis and treatment for different syndrome types of precocious puberty remain insufficiently studied.

In this study, the investigators will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of Sanghe Jianghuo Granules on the regulation of the hypothalamic-pituitary-gonadal (HPG) axis, metabolic homeostasis and inflammatory microenvironment, so as to verify its efficacy and safety. Furthermore, combined with transcriptomics, proteomics and network pharmacology, the investigators will identify the key targets and action pathways of Sanghe Jianghuo Granules, and verify its regulatory effect on the HPG axis through in vivo and in vitro experiments.

02

Conditions studied

  • Precocious Puberty

Browse trials for

Keywords

  • Precocious Puberty
  • Sanghe Jianghuo Granules
  • Traditional Chinese Medicine
  • Phlegm-Dampness Syndrome
03

Who can participate

Ages eligible
5 Years to 9 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Female, aged between 5 and 9 years (inclusive).
  2. Presence of secondary sexual characteristics before 8 years of age, consistent with simple premature thelarche / initial central precocious puberty (CPP) / Tanner stage II.
  3. Traditional Chinese Medicine (TCM) syndrome differentiation: Phlegm-dampness internal accumulation syndrome.
  4. Body mass index (BMI) greater than the 50th percentile for same age and sex.
  5. Initial case, no prior medication for precocious puberty (including but not limited to GnRHa, sex hormones, growth hormones, Zhibai Dihuang Wan, Dabuyin Wan, or traditional Chinese weight-loss medicines) within the last 3 months.
  6. Informed consent signed by the legal guardian(s), with ability to comply with the follow-up schedule.

Exclusion criteria

Exclusion Criteria:

  1. Secondary precocious puberty due to central nervous system organic lesions, thyroid or adrenal disorders, ovarian tumors, or other underlying conditions.
  2. Severe hepatic or renal dysfunction, or hematological diseases.
  3. Use of sex hormones, growth hormones, Zhibai Dihuang Wan, Dabuyin Wan, or traditional Chinese weight-loss medicines within the last 3 months.
  4. Inability to cooperate with examinations or poor compliance with follow-up visits (e.g., inability to complete ultrasound, blood collection, or scheduled visits).
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Sanghe Jianghuo Granules

    Participants receive Sanghe Jianghuo Granules orally, twice daily (dosage based on body weight), for 3 consecutive months. All participants also receive standardized lifestyle guidance for precocious puberty.

    Drug: Sanghe Jianghuo Granules

  • Placebo comparator
    Placebo

    Participants receive placebo (10% active-component, matching appearance, taste, and packaging of Sanghe Jianghuo Granules) orally, twice daily, for 3 consecutive months. All participants also receive standardized lifestyle guidance for precocious puberty.

    Combination Product: Placebo

Interventions

  • DrugSanghe Jianghuo Granules

    Composition: Mori Folium (Sang Ye), Nelumbinis Folium (He Ye), Rehmanniae Radix (Sheng Di), Anemarrhenae Rhizoma (Zhi Mu), Scutellariae Radix (Huang Qin), Atractylodis Macrocephalae Rhizoma (Bai Zhu), and other ingredients. Formulation: Granules. Administration: Oral, twice daily. Dosage: Based on body weight. Duration: 3 consecutive months.

  • Combination productPlacebo

    10% active-component placebo, matching the appearance, taste, and packaging of Sanghe Jianghuo Granules. Administration: Oral, twice daily. Duration: 3 consecutive months.

05

What researchers measure

Primary outcomes

  1. Breast Nodule Regression Rate

    Percentage reduction in breast nodule diameter at Week 12 compared to baseline, calculated as (baseline diameter - Week 12 diameter) / baseline diameter × 100%. Breast nodule diameter is measured by physical examination (palpation and/or ultrasound).

    Time frame: Baseline (Day 0) and Week 12

Secondary outcomes

  1. Uterine Volume

    Uterine volume measured by transabdominal ultrasound. Volume is calculated using the formula: V = (π/6) × length × anteroposterior diameter × transverse diameter, reported in cubic centimeters (cm³).

    Time frame: Baseline (Day 0) and Week 12

  2. Ovarian Volume

    Ovarian volume measured by transabdominal ultrasound. Volume is calculated using the formula: V = (π/6) × length × anteroposterior diameter × transverse diameter, reported in cubic centimeters (cm³).

    Time frame: Baseline (Day 0) and Week 12

  3. Follicle Diameter

    Maximum follicle diameter measured by transabdominal ultrasound, reported in millimeters (mm).

    Time frame: Baseline (Day 0) and Week 12

  4. Serum Luteinizing Hormone (LH)

    Serum LH level measured by chemiluminescent immunoassay, reported in U/L. Blood samples are collected in the morning after an overnight fast.

    Time frame: Baseline (Day 0) and Week 12

  5. Serum Follicle-Stimulating Hormone (FSH)

    Serum FSH level measured by chemiluminescent immunoassay, reported in U/L. Blood samples are collected in the morning after an overnight fast.

    Time frame: Baseline (Day 0) and Week 12

  6. Traditional Chinese Medicine (TCM) Syndrome Score

    TCM syndrome score assessed based on clinical evaluation of key symptoms including: preference for meat over vegetables, hyperactivity/restlessness, and greasy tongue coating. Higher scores indicate more severe syndrome manifestations.

    Time frame: Baseline (Day 0), Week 4, Week 8, and Week 12

  7. Body Mass Index (BMI)

    BMI calculated as weight (kg) divided by height squared (m²). Weight is measured using an electronic scale (kg, accurate to 0.1 kg). Height is measured using a mechanical height measuring device (cm, accurate to 0.1 cm).

    Time frame: Baseline (Day 0) and Week 12

06

Study locations

5 sites
  • Xiamen Children's Hospital
    Xiamen, Fujian, China
  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine
    Guangzhou, Guangdong 510405, China
  • The First Affiliated Hospital of Henan University of Chinese Medicine
    Zhengzhou, Henan 450000, China
  • Affiliated Hospital of Shandong University of TCM
    Jinan, Shandong 250011, China
  • Children's Hospital of Fudan University
    Shanghai, Shanghai Municipality 210102, China
    • Jian Yu · Contact · yuj@shmu.edu.cn · +86 13816881206
    • Wenqin Wang · Contact · +86 15001741617
07

Registry details

Key details

Study ID
NCT07637019
Lead sponsor
Children's Hospital of Fudan University
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Mar 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jun 9, 2026

Study contacts

Jian Yu, PhD
Contact
yuj@shmu.edu.cn
+86 13816881206

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion